{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T21:46:48Z","timestamp":1794865608656,"version":"4.9.1"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100013207","name":"Reckitt Benckiser Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013207","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug and Alcohol Dependence"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.drugalcdep.2019.107709","type":"journal-article","created":{"date-parts":[[2019,11,2]],"date-time":"2019-11-02T18:40:21Z","timestamp":1572720021000},"page":"107709","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":50,"special_numbering":"C","title":["Gabapentin drug misuse signals: A pharmacovigilance assessment using the FDA adverse event reporting system"],"prefix":"10.1016","volume":"206","author":[{"given":"Rachel","family":"Vickers-Smith","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiangwen","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J.","family":"Charnigo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle R.","family":"Lofwall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon L.","family":"Walsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer R..","family":"Havens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drugalcdep.2019.107709_bib0005","series-title":"PhViD: An R Package for Pharmacovigilance Signal Detection","author":"Ahmed","year":"2016"},{"key":"10.1016\/j.drugalcdep.2019.107709_bib0010","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1159\/000355268","article-title":"Gabapentinoid abuse in order to potentiate the effect of methadone: a survey among substance misusers","volume":"20","author":"Baird","year":"2014","journal-title":"Eur. Addict. Res."},{"key":"10.1016\/j.drugalcdep.2019.107709_bib0015","doi-asserted-by":"crossref","DOI":"10.1038\/sdata.2016.26","article-title":"A curated and standardized adverse drug event resource to accelerate drug safety research","volume":"3","author":"Banda","year":"2016","journal-title":"Sci. Data"},{"key":"10.1016\/j.drugalcdep.2019.107709_bib0020","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s002280050466","article-title":"A Bayesian neural network method for adverse drug reaction signal generation","volume":"54","author":"Bate","year":"1998","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.drugalcdep.2019.107709_bib0025","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.drugalcdep.2005.10.008","article-title":"The acute effects of gabapentin in combination with alcohol in heavy drinkers","volume":"83","author":"Bisaga","year":"2006","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2019.107709_bib0030","doi-asserted-by":"crossref","first-page":"661","DOI":"10.2165\/11536200-000000000-00000","article-title":"A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin","volume":"49","author":"Bockbrader","year":"2010","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.drugalcdep.2019.107709_bib0035","series-title":"Questions and Answers on FDA\u2019s Adverse Event Reporting System (FAERS) [WWW Document]","author":"Center for Drug Evaluation and Research","year":"2018"},{"key":"10.1016\/j.drugalcdep.2019.107709_bib0040","series-title":"FDA Adverse Event Reporting System (FAERS) - FDA Adverse Event Reporting System (FAERS): Latest Quarterly Data Files [WWW Document]","author":"Center for Drug Evaluation and Research","year":"2018"},{"key":"10.1016\/j.drugalcdep.2019.107709_bib0045","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s40263-016-0359-y","article-title":"A decade of gabapentinoid misuse: an analysis of the European Medicines Agency\u2019s \u2018Suspected adverse drug reactions\u2019 database","volume":"30","author":"Chiappini","year":"2016","journal-title":"CNS Drugs"},{"key":"10.1016\/j.drugalcdep.2019.107709_bib0050","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1111\/j.1365-2125.2011.04087.x","article-title":"When to publish measures of disproportionality derived from spontaneous reporting databases?","volume":"72","author":"de Boer","year":"2011","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.drugalcdep.2019.107709_bib0055","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/BF02116226","article-title":"Mechanisms of postural ataxia after intake of alcohol","volume":"90","author":"Diener","year":"1983","journal-title":"Z. Rechtsmed."},{"key":"10.1016\/j.drugalcdep.2019.107709_bib0060","series-title":"CDC Guideline for Prescribing Opioids for Chronic Pain - United States, 2016, MMWR: Recommendations and Reports","author":"Dowell","year":"2016"},{"key":"10.1016\/j.drugalcdep.2019.107709_bib0065","series-title":"Guideline on the Use of Statistical Signal Detection Methods in the EudraVigilance Data Analysis System","author":"European Medicines Agency","year":"2006"},{"key":"10.1016\/j.drugalcdep.2019.107709_bib0070","series-title":"EMCDDA-Europol 2012 Annual Report on the Implementation of Council Decision 2005\/387\/JHA","author":"European Monitoring Centre for Drugs and Drug Addiction","year":"2012"},{"key":"10.1016\/j.drugalcdep.2019.107709_bib0075","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/pds.677","article-title":"Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports","volume":"10","author":"Evans","year":"2001","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"10.1016\/j.drugalcdep.2019.107709_bib0080","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1212\/WNL.44.5.982","article-title":"Lack of serious toxicity following gabapentin overdose","volume":"44","author":"Fischer","year":"1994","journal-title":"Neurology"},{"key":"10.1016\/j.drugalcdep.2019.107709_bib0085","first-page":"266","article-title":"Gabapentin use in a managed medicaid population","volume":"8","author":"Hamer","year":"2002","journal-title":"J. Manag. Care Pharm."},{"key":"10.1016\/j.drugalcdep.2019.107709_bib0090","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1592\/phco.24.8.743.36068","article-title":"Replication of the weber effect using postmarketing adverse event reports voluntarily submitted to the united states food and drug administration","volume":"24","author":"Hartnell","year":"2004","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.drugalcdep.2019.107709_bib0095","doi-asserted-by":"crossref","first-page":"385","DOI":"10.2165\/00002018-200629050-00003","article-title":"Under-reporting of adverse drug reactions","volume":"29","author":"Hazell","year":"2006","journal-title":"Drug Saf."},{"key":"10.1016\/j.drugalcdep.2019.107709_bib0100","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1177\/0091270009333484","article-title":"Systematic investigation of time windows for adverse event data mining for recently approved drugs","volume":"49","author":"Hochberg","year":"2009","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.drugalcdep.2019.107709_bib0105","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/bcp.12277","article-title":"Misuse of the gamma-aminobutyric acid analogues baclofen, gabapentin and pregabalin in the UK","volume":"78","author":"Kapil","year":"2014","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.drugalcdep.2019.107709_bib0110","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1046\/j.1365-2125.1997.00615.x","article-title":"Reports of hypoglycaemia associated with the use of ACE inhibitors and other drugs: a case\/non-case study in the French pharmacovigilance system database","volume":"44","author":"Moore","year":"1997","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.drugalcdep.2019.107709_bib0115","doi-asserted-by":"crossref","first-page":"480","DOI":"10.21105\/joss.00480","article-title":"Phonetic algorithms in R","volume":"3","author":"Howard","year":"2018","journal-title":"J. Open Source Softw."},{"key":"10.1016\/j.drugalcdep.2019.107709_bib0120","doi-asserted-by":"crossref","first-page":"891","DOI":"10.2165\/00002018-200730100-00007","article-title":"Impact of safety alerts on measures of disproportionality in spontaneous reporting databases","volume":"30","author":"Pariente","year":"2007","journal-title":"Drug Saf."},{"key":"10.1016\/j.drugalcdep.2019.107709_bib0125","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1093\/jat\/33.8.545","article-title":"Prevalence of gabapentin in impaired driving cases in Washington State in 2003-2007","volume":"33","author":"Peterson","year":"2009","journal-title":"J. Anal. Toxicol."},{"key":"10.1016\/j.drugalcdep.2019.107709_bib0130","series-title":"Data Mining Applications in Engineering and Medicine","article-title":"Data mining techniques in pharmacovigilance: analysis of the publicly accessible FDA adverse event reporting system (AERS)","author":"Poluzzi","year":"2012"},{"key":"10.1016\/j.drugalcdep.2019.107709_bib0135","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1001\/archinte.166.9.1021","article-title":"Off-label prescribing among office-based physicians","volume":"166","author":"Radley","year":"2006","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.drugalcdep.2019.107709_bib0140","first-page":"16","article-title":"Abuse of combinations of gabapentin and quetiapine","volume":"16","author":"Reeves","year":"2014","journal-title":"Prim. Care Companion CNS Disord."},{"key":"10.1016\/j.drugalcdep.2019.107709_bib0145","doi-asserted-by":"crossref","DOI":"10.1176\/appi.ajp.2014.13111526","article-title":"Potentiation of the effect of buprenorphine\/naloxone with gabapentin or quetiapine","author":"Reeves","year":"2014","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.drugalcdep.2019.107709_bib0150","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1002\/pds.615","article-title":"The role of databases in drug postmarketing surveillance","volume":"10","author":"Rodriguez","year":"2001","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"10.1016\/j.drugalcdep.2019.107709_bib0155","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1053\/smrv.2001.0162","article-title":"Sleep, sleepiness, sleep disorders and alcohol use and abuse","volume":"5","author":"Roehrs","year":"2001","journal-title":"Sleep Med. Rev."},{"key":"10.1016\/j.drugalcdep.2019.107709_bib0160","doi-asserted-by":"crossref","first-page":"e64","DOI":"10.1176\/appi.neuropsych.13110339","article-title":"Gabapentin dependence in a patient with opioid dependence syndrome","volume":"27","author":"Satish","year":"2015","journal-title":"J. Neuropsychiatry Clin. Neurosci."},{"key":"10.1016\/j.drugalcdep.2019.107709_bib0165","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1093\/jat\/bkv134","article-title":"Comprehensive duloxetine analysis in a fatal overdose","volume":"40","author":"Scanlon","year":"2016","journal-title":"J. Anal. Toxicol."},{"key":"10.1016\/j.drugalcdep.2019.107709_bib0170","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1159\/000321079","article-title":"Is there a recreational misuse potential for pregabalin? Analysis of anecdotal online reports in comparison with related gabapentin and clonazepam data","volume":"80","author":"Schifano","year":"2011","journal-title":"Psychother. Psychosom."},{"key":"10.1016\/j.drugalcdep.2019.107709_bib0175","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1007\/s00228-010-0853-y","article-title":"A signal for an abuse liability for pregabalin\u2014results from the Swedish spontaneous adverse drug reaction reporting system","volume":"66","author":"Schwan","year":"2010","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.drugalcdep.2019.107709_bib0180","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1016\/j.pain.2013.05.053","article-title":"Classification and definition of misuse, abuse, and related events in clinical trials: ACTTION systematic review and recommendations","volume":"154","author":"Smith","year":"2013","journal-title":"Pain"},{"key":"10.1016\/j.drugalcdep.2019.107709_bib0185","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1111\/add.13324","article-title":"Gabapentin misuse, abuse and diversion: a systematic review","volume":"111","author":"Smith","year":"2016","journal-title":"Addiction"},{"key":"10.1016\/j.drugalcdep.2019.107709_bib0190","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1176\/appi.ajp.2014.14101272","article-title":"Abuse and diversion of gabapentin among nonmedical prescription opioid users in Appalachian Kentucky","volume":"172","author":"Smith","year":"2015","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.drugalcdep.2019.107709_bib0195","doi-asserted-by":"crossref","first-page":"381","DOI":"10.2165\/00002018-200225060-00001","article-title":"Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA\u2019s spontaneous reports database","volume":"25","author":"Szarfman","year":"2002","journal-title":"Drug Saf."},{"key":"10.1016\/j.drugalcdep.2019.107709_bib0200","series-title":"2005 - Placement of Pregabalin Into Schedule V [WWW Document]","author":"U.S. Department of Justice Drug Enforcement Administration Diversion Control Division","year":"2005"},{"key":"10.1016\/j.drugalcdep.2019.107709_bib0205","series-title":"Center for Drug Evaluation and Research 2015-2016 Drug Safety Priorities: Initiatives and Innovation","author":"U.S. Food and Drug Administration","year":"2016"},{"key":"10.1016\/j.drugalcdep.2019.107709_bib0210","series-title":"Lyrica (Pregabalin) Capsules Drug Approval Package [WWW Document]","author":"U.S. Food and Drug Administration","year":"2005"},{"key":"10.1016\/j.drugalcdep.2019.107709_bib0215","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/pds.668","article-title":"A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions","volume":"11","author":"van Puijenbroek","year":"2002","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"10.1016\/j.drugalcdep.2019.107709_bib0220","doi-asserted-by":"crossref","DOI":"10.1037\/adb0000337","article-title":"A qualitative analysis of gabapentin misuse and diversion among people who use drugs in Appalachian Kentucky","volume":"32","author":"Vickers Smith","year":"2018","journal-title":"Psychol. Addict. Behav."},{"key":"10.1016\/j.drugalcdep.2019.107709_bib0225","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.2165\/11584390-000000000-00000","article-title":"An Experimental Investigation of Masking in the US FDA Adverse Event Reporting System Database","volume":"33","author":"Wang","year":"2010","journal-title":"Drug Saf."},{"key":"10.1016\/j.drugalcdep.2019.107709_bib0230","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/ajad.12159","article-title":"Prescription medication misuse among opioid dependent patients seeking inpatient detoxification","volume":"24","author":"Wilens","year":"2015","journal-title":"Am. J. Addict."},{"key":"10.1016\/j.drugalcdep.2019.107709_bib0235","series-title":"Lexicon of Alcohol and Drug Terms Published by the World Health Organization [WWW Document], URL","author":"World Health Organization","year":"2015"},{"key":"10.1016\/j.drugalcdep.2019.107709_bib0240","series-title":"WHO | Pharmacovigilance [WWW Document]","author":"World Health Organization","year":"2015"},{"key":"10.1016\/j.drugalcdep.2019.107709_bib0245","series-title":"Safety Monitoring of Medicinal Products","author":"World Health Organization","year":"2012"},{"key":"10.1016\/j.drugalcdep.2019.107709_bib0250","first-page":"e244","article-title":"Problematic pregabalin and gabapentin use: results from the canada vigilance adverse reaction online database","volume":"156","author":"Zhang","year":"2015","journal-title":"Drug Alcohol Depend."}],"container-title":["Drug and Alcohol Dependence"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0376871619304867?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0376871619304867?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T09:02:48Z","timestamp":1759827768000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0376871619304867"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":50,"alternative-id":["S0376871619304867"],"URL":"https:\/\/doi.org\/10.1016\/j.drugalcdep.2019.107709","relation":{},"ISSN":["0376-8716"],"issn-type":[{"value":"0376-8716","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Gabapentin drug misuse signals: A pharmacovigilance assessment using the FDA adverse event reporting system","name":"articletitle","label":"Article Title"},{"value":"Drug and Alcohol Dependence","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drugalcdep.2019.107709","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107709"}}